Case Report: Generating Hypotheses by Discovering Implicit Associations in the Literature: A Case Report of a Search for New Potential Therapeutic Uses for Thalidomide

The availability of scientific bibliographies through online databases provides a rich source of information for scientists to support their research. However, the risk of this pervasive availability is that an individual researcher may fail to find relevant information that is outside the direct scope of interest. Following Swanson's ABC model of disjoint but complementary structures in the biomedical literature, we have developed a discovery support tool to systematically analyze the scientific literature in order to generate novel and plausible hypotheses. In this case report, we employ the system to find potentially new target diseases for the drug thalidomide. We find solid bibliographic evidence suggesting that thalidomide might be useful for treating acute pancreatitis, chronic hepatitis C, Helicobacter pylori-induced gastritis, and myasthenia gravis. However, experimental and clinical evaluation is needed to validate these hypotheses and to assess the trade-off between therapeutic benefits and toxicities.

[1]  J. Wingard,et al.  Thalidomide in Children Undergoing Bone Marrow Transplantation: Series at a Single Institution and Review of the Literature , 1999, Pediatrics.

[2]  J. Thèze,et al.  The cytokine network and immune functions , 1999 .

[3]  A. Saoudi,et al.  Is pathogenic humoral autoimmunity a Th1 response? , 2000, Immunology today.

[4]  Marc Weeber,et al.  Using concepts in literature-based discovery: Simulating Swanson's Raynaud-fish oil and migraine-magnesium discoveries , 2001, J. Assoc. Inf. Sci. Technol..

[5]  N R Smalheiser,et al.  Using ARROWSMITH: a computer-assisted approach to formulating and assessing scientific hypotheses. , 1998, Computer methods and programs in biomedicine.

[6]  D. Adams,et al.  Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. , 1999, Journal of immunology.

[7]  R. Pezzilli,et al.  Behavior of serum interleukin 12 in human acute pancreatitis. , 1999, Pancreas.

[8]  J. Devière,et al.  Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice , 1998, Gut.

[9]  Neil R. Smalheiser,et al.  Artificial Intelligence An interactive system for finding complementary literatures : a stimulus to scientific discovery , 1995 .

[10]  D F Roychowdhury,et al.  Aspirin and the risk of colorectal cancer in women. , 1996, The New England journal of medicine.

[11]  N. Raje,et al.  Thalidomide--a revival story. , 1999, The New England journal of medicine.

[12]  R. Powell,et al.  New roles for thalidomide , 1996, BMJ.

[13]  R. Pirskanen,et al.  Decreased mRNA expression of TNF‐α and IL‐10 in non‐stimulated peripheral blood mononuclear cells in myasthenia gravis , 2000, European journal of neurology.

[14]  D. Swanson Migraine and Magnesium: Eleven Neglected Connections , 2015, Perspectives in biology and medicine.

[15]  J. McHutchison,et al.  A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[16]  Marc Weeber,et al.  Text-based discovery in biomedicine: the architecture of the DAD-system , 2000, AMIA.

[17]  G. Trinchieri,et al.  Inhibition of IL-12 production by thalidomide. , 1997, Journal of immunology.

[18]  H. Yagita,et al.  Suppressive effect on Theiler's murine encephalomyelitis virus-induced demyelinating disease by the administration of anti-IL-12 antibody. , 1998, Journal of immunology.

[19]  V. Rivera,et al.  Immunoregulation and blocking antibodies induced by interferon beta treatment in MS , 2000, Neurology.

[20]  C. McKay,et al.  Increased monocyte cytokine production in association with systemic complications in acute pancreatitis , 1996, The British journal of surgery.

[21]  J A Quiroga,et al.  Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage. , 1998, The Journal of infectious diseases.

[22]  B. Sands,et al.  New life in a sleeper: thalidomide and Crohn's disease. , 1999, Gastroenterology.

[23]  F Charatan First pill for male impotence approved in US , 1998, BMJ.

[24]  D. Swanson Fish Oil, Raynaud's Syndrome, and Undiscovered Public Knowledge , 2015, Perspectives in biology and medicine.

[25]  P. Haslett,et al.  Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.

[26]  G. Lauer,et al.  Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. , 1997, Journal of hepatology.

[27]  A. Pestronk,et al.  The effect of thalidomide on experimental autoimmune myasthenia gravis. , 1989, Journal of autoimmunity.

[28]  Ken B. Waites,et al.  Helicobacter pylori-Induced Mucosal Inflammation Is Th1 Mediated and Exacerbated in IL-4, But Not IFN-γ, Gene-Deficient Mice1 , 2000, The Journal of Immunology.

[29]  T G Blanchard,et al.  Review article: Immunological determinants that may affect the Helicobacter pylori cancer risk. , 1998, Alimentary pharmacology & therapeutics.

[30]  G Muller,et al.  Thalidomide as an emerging immunotherapeutic agent. , 1999, Immunology today.

[31]  Yoshiyuki Ueno,et al.  Profiles of cytokines produced by CD4-positive T lymphocytes stimulated by anti-CD3 antibody in patients with chronic hepatitis C , 1998, Journal of Gastroenterology.

[32]  M. Pirisi,et al.  Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to IFN-alpha in chronic hepatitis C. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[33]  P Nieuwenhuis,et al.  Single expression of CD45RC and RT6 in correlation with T-helper 1 and T-helper 2 cytokine patterns in the rat. , 2000, Cellular immunology.

[34]  S. Joshi‐Barve,et al.  Cytokine Production by CAPAN-1 and CAPAN-2 Cell Lines , 2000, Digestive Diseases and Sciences.

[35]  R A Miller,et al.  Making the conceptual connections: the Unified Medical Language System (UMLS) after a decade of research and development. , 1998, Journal of the American Medical Informatics Association : JAMIA.

[36]  P. Marcellin,et al.  Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. , 1999, Journal of hepatology.

[37]  R. Callard,et al.  The cytokine factsbook , 1994 .

[38]  R. Pirskanen,et al.  Tumor necrosis factor-α, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis , 1996, Journal of Neuroimmunology.

[39]  Stewart,et al.  Iron absorption in patients with Zollinger–Ellison syndrome treated with long‐term gastric acid antisecretory therapy , 1998, Alimentary pharmacology & therapeutics.

[40]  Rein Vos,et al.  Drugs Looking for Diseases , 1991, Developments in Cardiovascular Medicine.

[41]  Don R. Swanson,et al.  Complementary structures in disjoint science literatures , 1991, SIGIR '91.

[42]  S. Ashley,et al.  Interleukin 10 reduces the severity of acute pancreatitis in rats. , 1997, Gastroenterology.

[43]  P S Sastry,et al.  Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis. , 1999, Medical hypotheses.

[44]  G. Bishop,et al.  Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1‐associated cytokines , 1996, Hepatology.

[45]  Susan Mayor Trial supports earlier screening for Down's syndrome , 1998 .

[46]  R A Lawrence,et al.  The effects of early pacifier use on breastfeeding duration. , 1999, Pediatrics.

[47]  C M Lockwood,et al.  The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen‐ and antigen‐stimulated human peripheral blood mononuclear cell cultures , 1995, Clinical and experimental immunology.

[48]  Alan R. Aronson,et al.  Effective mapping of biomedical text to the UMLS Metathesaurus: the MetaMap program , 2001, AMIA.

[49]  A. Fleischer,et al.  Thalidomide: current and potential clinical applications. , 2000, The American journal of medicine.

[50]  V H Price,et al.  Treatment of hair loss. , 1999, The New England journal of medicine.

[51]  Š. Mesaroš,et al.  Interleukin-12 and tumor necrosis factor-α levels in cerebrospinal fluid of multiple sclerosis patients , 1997, Journal of the Neurological Sciences.

[52]  J. Raufman,et al.  Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C , 2001, American Journal of Gastroenterology.